Observational GLP-1s for Longevity

With help from the AgelessRx GLP-1 community, our Applied Science team aims to demonstrate the longevity benefits of oral and injectable GLP-1s beyond weight loss.

Microdosing GLP-1s for Longevity

Could microdosing GLP-1s make the longevity benefits of Semaglutide more accessible? Our Applied Science team aims to answer this emerging question, exploring whether small doses of GLP-1 could improve pain, brain fog, and symptoms of chronic inflammation.

Commercial Biobanking for Longevity

By contributing blood, plasma, or serum samples, you’ll play a crucial role in shaping the future of personalized longevity treatments to uncover how these interventions impact key aging biomarkers—paving the way for more targeted, science-backed applications in the future.

Life after GLP-1s

How can patients best maintain their weight loss benefits once they stop taking GLP-1 medications? Is it better to slowly wean off, or ease into another weight loss solution? This trial explores potential strategies to help patients sustain their Semaglutide or Tirzepatide benefits for the long term.

Observational Sleep for Longevity

An exploration into the efficacy of Trazodone and Tran-Q Sleep on healthy longevity. By evaluating improvements in the quality and quantity of sleep, this trial aims to show how healthy sleep may slow biological aging to improve immunity, cognitive health, and quality of life.

Rapamycin & Oral Health

Can Rapamycin slow or even reverse periodontal disease, gum inflammation, or bone loss? The AgelessRx research team investigates the possible benefits of Rapamycin on oral health, based on promising findings from the PEARL trial.

Rapamycin & DEXA Scan

Using DEXA scans to measure Rapamycin’s efficacy, the research team expands on preliminary findings from the PEARL trial that suggest Rapamycin may improve muscle mass and bone mineral density—all critical for healthy functionality as we age.

PEARL Trial

The PEARL Trial is the first large-scale intervention trial on longevity—and one of the first studies to show that low-dose, intermittent Rapamycin is safe for healthy adults. Explore the potential benefits of Rapamycin and read the trial results.

Post-COVID Trial

A double-blind, placebo-controlled pilot study that shows how LDN and NAD+ improved quality of life and energy for post-COVID patients after 12 weeks, suggesting that the combination of these treatments may be effective in the fight against long COVID.

Canagliflozin Study

This research trial measured the safety, tolerability, and glucose benefits of Canagliflozin in eliminating excess blood sugar in healthy individuals, opening the door for further studies for enhancing healthy longevity and preventing age-related diseases.

Rapamycin Bioavailability Study

A cross-sectional study comparing Rapamycin blood levels for compounded versus generic Rapamycin to guide personalized prescription for individual health goals. Discover how the same dose of Rapamycin varies per person, and learn which may be right for you.

Acarbose Study

Using just a bagel, Acarbose, and a CGM, this trial measured the effects of Acarbose in a healthy individual before and after eating a high-carbohydrate meal, showing that this treatment helps stop glucose spikes in their tracks.

Rapamycin & LDN for Bone Mineral Density

A clinical case study of a 52-year-old woman taking both Rapamycin and LDN to treat reduced bone miner density (BMD). Discover how this cutting-edge combination therapy emerges as a potential treatment for prevalent bone disorders like osteopenia and osteoporosis.